Thursday, April 27, 2023

Zura Bio Gets $80M In PIPE

San Diego-based biotechnology developer Zura Bio, a publicly traded biotech company focused on developing treatments for immune and inflammatory disorders, says it has received $80M in a financing. The company--which trades on the Nasdaq as ZURA--said the private placement was Deep Track Capital, Great Point Partners, Suvretta Capital, plus an un-named life sciences-focused investment fund, plus other new and existing investors. The company said the financing came as a result of a license from Eli Lilly and Company for a new compound aimed at treating autoimmune diseases.